Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Prior treatment

• Had used bevacizumab within 6 months of enrollment
• The patient had Recent intestinal obstruction, gastrointestinal perforation within 3 months, uncontrolled high blood pressure after medication (Systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg), Moderate to severe cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), moderate to severe deep vein thrombosis and moderate to severe pulmonary embolism occurred within 6 months before enrollment. Patient with coagulation dysfunction.

Other illness

• Has combined with other malignant tumor which diagnosed within 5 years and/or needed to be treated. The patients had untreated CNS metastases.
• Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for congestive heart failure
• Activity or uncontrol severe infection

• Ovarian cancer patients with histopathological type: low/high grade serous carcinoma, endometrioid carcinoma,had received platinum-based regimens for at least 1-3 lines after primary cytoreductive surgery.
• The patient had at least one measurable lesion according to the RECIST V1.1 criteria.
• The time from the last cycle of chemotherapy to relapse/progression should be more than 6 months.
• ECOG score 0\~1,age 18\~75 years old
• The serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial
• CBC Hb≥90g/L, ANC≥1.5×109/L, PLT≥100×109/L,
• Serum ALT≤3×UL, AST≤3×ULN#Serum creatinine≤1.5×ULN#